Supplementary information

Trends in the use of liquid biopsy in oncology

In the format provided by the authors

Clinical trial database construction and analysis

We constructed a proprietary liquid biopsy clinical trial database, which has four components:


- Basic information on the liquid biopsy product: application (therapy guidance, therapy monitoring, residual disease monitoring or early detection), name of product, test manufacturer (test company) and biopharma company collaborator
- Clinical trial information: NCT number, trial title, summary, trial name, phase, start and finish date, current status, country, drug included in the trial, drug type (targeted therapy, chemo, immunotherapy etc.), trial design, cancer indication, size of trial (number of patients), trial outcome (sensitivity, specificity)
- Regulatory status: current regulatory status (in vitro diagnostic (IVD) or laboratorydeveloped test (LDT), approval entity, approval time
- Technology: next-generation sequencing (NGS)/PCR, panel size, sample type (such as blood, other plasma tissues) etc.

The database was constructed via combined bottom-up and top-down processes:


- Top-down approach:
 - First, we obtained a list of any relevant clinical trials by keyword searching for tumour biomarkers, such as ctDNA, ctRNA, extracellular vesicles and circulating tumour cells. A total of ~3,500 trials were obtained with this process.
 - Second, we further scrutinized the results to select the trials that are relevant to liquid biopsy based on the following exclusion criteria:
 - 1) trials not relevant to oncology, such as trials using liquid biopsy technology for acute kidney injury, transplant failure and infectious diseases
 - trials with primarily focus of drug development but included a routine use of diagnostic tests for circulating tumour cells or circulating T cells for blood cancers such as leukaemias and lymphomas
 - 3) trials that only have liquid biopsy as an exploratory objective or exploratory outcome
 - 4) trials primarily assessed tissues other than liquid tissues
 - 5) trials suspended, withdrawn or terminated prematurely.
- Bottom-up approach:
 - First, we compiled a list of key companies and their major products in the liquid biopsy field sourced from analyst reports and literature review. A total of 134 major liquid biopsy and NGS companies were identified.
 - Second, we searched each company's website and company reports (such as 10K filings and investor presentations) to obtain a list of their products and clinical trials. We then searched ClinicalTrials.gov for their major products.

The bottom-up approach results were largely overlapping with those from the top-down approach, so we matched the trials via their NCT numbers to ensure no duplication in the database.


Overall, \sim 1,500 relevant blood-based liquid biopsy trials in oncology were included in our analysis. Some emerging liquid biopsy analytes such as exosomes and RNA (miRNA and mRNA) are not fully captured in this database given that most of them are in the early exploratory phase with limited clinical application.



Supplementary Figure 1 | **Overall landscape of liquid biopsy clinical trials**. **A** | Active clinical trials by indication. **B** | Active oncology clinical trials by type of sample. **C** | Active oncology blood-sample-based clinical trials by type of substance. ¹Some trials may contain multiple types of samples, so the number does not add up to total number of trials. Source: ClinicalTrials.gov, company websites and financial reports, BCG analysis.



Supplementary Figure 2 | **Relevant trends in oncology clinical trials**. **A** | Clinical trials initiated in each year associated with genetic testing from 2007 to 2022. Note the liquid biopsy trials only include the therapy/outcome monitoring and guidance applications for fair comparison to tissue biopsy, and do not include early disease detection and residual disease monitoring applications. **B** | Number of immune-oncology drug candidates and targeted oncology drug candidates in preclinical studies and clinical trials from 2007 to 2022. Targeted drugs include protein kinase inhibitors and hormone receptor modulators. ¹2022 data include only January to November 2022. ²Source: ClinicalTrials.gov, NIH National Human Genome Research Institute, Citeline Pharmaprojects, Evaluate Pharma, BCG analysis.



Supplementary Figure 3 | **Trends in clinical trials assessing minimum residual disease** (MRD) to test drug effectiveness. A | The number of clinical trials conducted by biopharma aiming to use MRD to test drug effectiveness is increasing. B | Drug categories tested in MRD clinical trials. C | Indications tested in MRD clinical trials. Numbers in panel B and C refer to % trials. 'Other' includes head and neck cancer, brain tumors, ovarian cancer, renal cancer, melanoma, esophageal cancer and liver cancer. Trials that are not conducted by biopharma companies, with an undisclosed drug or without a drug, not aiming to test drug effectiveness, or with an undisclosed clinical phase, are not included. Source: ClinicalTrials.gov, BCG analysis.

Supplementary Tabl	Supplementary Table 1 Commercialized products for liquid biopsy						
Product	Company	Approval or	Panel size	Primary			
	1 0	launch status	category	application			
Abbott RealTime IDH1	Abbott Molecular	Launched 2018 Approved by FDA 2018	small	Therapy guidance			
Abbott RealTime IDH2	Abbott Molecular	Launched 2017 Approved by FDA 2017	small	Therapy guidance			
ARNA Breast	Arna Genomic	Launched n.a	small	Early detection			
AR-v7 assays	Epic Sciences	Launched n.a	small	Therapy guidance			
Astra TM	Genosity	Launched 2020	large	MRD			
AVENIO ctDNA Expanded Kit	Roche	Launched 2017	mid	Therapy monitoring			
AVENIO ctDNA Surveillance Kit	Roche	Launched 2017	mid	Therapy monitoring			
AVENIO ctDNA targeted kit	Roche	Launched 2017	small	Therapy monitoring			
BRACAnalysis CDx®	Myriad Genetics	Launched 2014, Approved 2014	small	Therapy guidance			
brProphet	Burning Rock Biotech	Launched n.a	large	MRD			
CancerSEEK	Thrive/Exact Sciences	Launched 2019	small	Early detection			
CatALLyst TM	Amgen	Launched 2022	unknown	Early detection			
CellSearch	Veridex	Launched 2004 Approved 2004	n/a	Therapy guidance			
clonoSEQ	Adaptive	Launched 2018 Approved 2018	small	MRD			
Cobas EGFR Mutation Test v2	Roche	Launched 2016, Approved by FDA 2018	small	Therapy guidance			
COLVERA	Clinical Genomics	Launched 2016	small	MRD			
Epi proColon	Epigenomics	Launched 2016 Approved 2016	small	Early detection			
Epi proLung	Epigenomics	Launched n.a	small	Early detection			
FoundationACT	Foundation Medicine	Launched 2017	mid	Therapy monitoring			
FoundationOne Heme	Foundation Medicine	Launched 2013	large	Therapy monitoring			
FoundationOne®	Foundation	Launched 2020,	large	Therapy guidance			
Liquid CDx	Medicine	Approved 2020	large				
Freenome multianalyte test for colon cancer	Freenome	Launched 2014	(blank)	Early detection			
Galleri	Grail/Illumina	Launched 2021	large	Early detection			
Guardant Reveal	Guardant Health	Launched 2021	large	MRD			
Guardant360	Guardant Health	Launched 2014, Approved 2014	small	Therapy guidance			

Supplementary Table 1 | Commercialized products for liquid biopsy

Guardant360 LDT	Guardant Health	Launched 2020	mid	Therapy monitoring
IdyllaTM ctBRAF Mutation Assay	Biocartis	Launched n.a	small	Therapy guidance
IdyllaTM ctKRAS Mutation Assay	Biocartis	Launched 2016	small	Therapy guidance
IdyllaTM ctNRAS -BRAF Mutation Assay	Biocartis	Launched n.a	small	Therapy guidance
Idylla [™] ctEGFR Mutation Assay	Biocartis	Launched 2015	small	Therapy guidance
InvisionFirst®	Inivata	Launched 2020	small	MRD
KIT D816V Assay	ARUP Laboratories	Launched 2015, Approved 2015	small	Therapy guidance
LeukoStrat® CDx FLT3 Mutation Assay	Invivoscribe Technologies	Launched 2014 Approved 2017	small	Therapy guidance
Lunar 2	Guardant Health	Launched n.a	large	Early detection
LungLB	LungLifeAI	Launched 2022	large	Therapy guidance
MRDx BCR-ABL Test	MolecularMD/Icon	Launched 2017 Approved 2017	small	Therapy guidance
NavDx® HPV ctDNA testing	Naveris	Launched n.a	unknown	Early detection
OncoBEAM [™] RAS Colorecteral	Sysmex	Launched n.a	small	Therapy guidance
OncoCEE TM	Biocept	Launched 2011	unknown	Early detection
OncoCompass Target TM	Burning Rock Biotech	Launched 2021	small	Therapy guidance
Oncomine	Thermofisher	Launched 2017 Approved 2017	mid	Therapy guidance
Oncomine focus	Thermofisher	Launched 2015 Approved 2017	mid	Therapy guidance
Onconscreen plus 520 Panel	Burning Rock	Launched n.a	large	MRD
OncoReveal®	Pillar Biosciences	Launched 2021	large	Therapy guidance
OncoScreen Plus panel	AlphaGenomix	Launched n.a	large	Therapy guidance
Oncotype DX The Breast Recurrence Score®	Exact Sciences	Launched n.a	small	MRD
OncotypeSEQ Liquid Select assay	Genomic Health	Launched 2016	small	Therapy guidance
PANAMutyper [™] R EGFR	PNA Bio	Launched prior 2016	small	Therapy guidance
PANAMutyper [™] R KRAS	PNA Bio	Launched prior 2016	small	Therapy guidance

PANAMutyper TM				
R NRAS (31	PNA Bio	Launched prior	small	Therapy guidance
Mutations)		2016		Interp) garantee
РСМтм	ArcherDx/Invitae	Launched n.a	unknown	MRD
PGDx elio TM	PGDx	Launched 2018 Approved 2018	large	Therapy guidance
plasma resolve*				
POMC/PCSK1/LE	PreventionGenetics	Launched 2022	small	Therapy guidance
PR CDx Panel		Approved 2022		
PredicineCARE	Predicine	Launched 2022	mid	Therapy guidance
QIAamp	Qiagen	Launched prior	mid	Therapy
Qui iminp	Zingen	2019	11114	monitoring
	.	Launched 2021	11	
RaDAR	Inivata	Approved by	small	MRD
		FDA 2021		TT1
RadTox	Diacarta	Launched n.a	(blank)	Therapy
C'a matana	N. da wa	L		monitoring
Signatera	Natera	Launched 2021	small	MRD
Super-ARMS® EGFR kit	AmoyDx	Launched prior	small	Therapy guidance
		2017		
therascreen	0.	Launched 2019, Approved 2019	small	Therapy guidance
PIK3CA RGQ PCR Kit	Qiagen			
TheraSure CNI				
Monitor	Chronix	Launched 2018	small	MRD
TruSight				
Oncology 500	Illumina	Launched 2019	large	Therapy
(TSO500)	mumma	Launcheu 2019	large	monitoring
HCCscreen	Genetron	Launched 2021	unknown	Early detection
ColonAiQ	Singlera	Launched 2022	small	Therapy guidance
OverC [™] Multi-	¥	received CE		17.0
Cancer Early	Burning Rock	mark in May	large	Therapy guidance
Detection	Biotech	2022	0	1
BGI SENTIS™ C		received CE		
ancer + Discovery	BGI	mark in May	large	Therapy guidance
Panel		2021		
GENESEEQLITE	ConoSoog	Launahad 2021	mid	Th
ТМ	GeneSeeq	Launched 2021	mid	Therapy guidance
BRCASCANTM	GeneSeeq	Launched n.a	small	Therapy guidance

MRD, minimum residual disease; n.a, not available.

References

- 1. Preethi KA, et al. Mol Cancer. 2022 Feb 16;21(1):54.
- 2. Galiveti CR, et al. Head Neck. 2023 Jan;45(1):212-224
- 3. Guo T, et al. Mol Cancer. 2022 Dec 12;21(1):21